Transition to Metastatic State: Lung Cancer, Pancreatic Cancer and Brain Metastasis

项目概要（整体单元） 转移体现了动态的，复杂的，整个有机体的癌症病理生理学。蔓延 原发肿瘤部位以外的癌细胞是大多数癌症死亡的原因， 癌症复杂进化动力学的明显表达。与错综复杂的 发展和免疫过程中，从局部侵袭性转移到癌症的转变， 一个重大的科学障碍最近的技术和计算进步，由我们的 团队能够对多种组织进行动态、多维、多平面分析。应用这些 美国最致命癌症的进展：肺癌、胰腺癌和中枢神经系统转移， 我们将生成一个具有前所未有的时空分辨率的人体组织图谱。这 多学科的努力始于一系列无与伦比的人体组织和临床数据， 我们的生物样本小组这些高质量的生物标本将从肺癌中获得， 从手术切除、活组织检查或尸检中获得的胰腺癌和CNS转移。数据 分析单位将对这些样本进行多维分析，包括 批量DNA测序，单细胞和单核RNA测序，以及结构上- 灵敏度分析包括MIBI（蛋白质）和MERFISH（RNA）技术。在革命的推动下， 计算和系统生物学家，这些数据集的整合和介绍将进行 由表征单位，目标是生成有价值的权威人类肿瘤图谱， 整个癌症研究界

PROJECT SUMMARY (Overall Unit) Metastasis embodies the dynamic, complex, whole-organism pathophysiology of cancer. Spread of cancer cells beyond the primary tumor site is the cause of the majority of cancer deaths and the most overt expression of cancer's complex evolutionary dynamics. Intimately related to the intricate processes of development and immunity, the transition from locally invasive to metastatic cancer poses a major scientific hurdle. Recent technological and computational advancements, pioneered by our team enable dynamic, multi-dimensional, multi-planar analysis of multiple tissues. Applying these advances to the most lethal cancers in the US: Lung Cancer, Pancreatic Cancer and CNS metastases, we will generate a Human Tissue Atlas with unprecedented spatial-temporal resolution. This multidisciplinary effort begins with an unparalleled array of human tissues and clinical data acquired by our Biospecimen Unit team. These high-quality biospecimens will be obtained from lung cancer, pancreatic cancer and CNS metastases obtained from surgical resections, biopsy or autopsy. The Data Analysis Unit will then subject these specimens will be subjected to multi-dimensional analysis including bulk DNA sequencing, single cell and single nuclear RNA sequencing, as well as architecturally- sensitive analyses including MIBI (protein) and MERFISH (RNA) technologies. Driven by revolutionary computational and systems biologists, integration and presentation of these datasets will be undertaken by the Characterization Unit, with the goal of generating authoritative human tumor atlases of value to the entire cancer research community.